Glucocorticosteroid therapy decreases CD14-expression and CD14-mediated LPS-binding and activation of monocytes in patients suffering from systemic lupus erythematosus

Clin Immunol. 2005 Dec;117(3):271-9. doi: 10.1016/j.clim.2005.09.002. Epub 2005 Nov 28.

Abstract

In order to study the possible action of glucocorticosteroids (GCS) on the CD14/Toll like receptor mediated activation of monocytes the CD14-expression, CD14-mediated LPS binding and activation of these cells of patients suffering from Systemic Lupus Erythematosus receiving no, low dose or pulse steroid treatment was studied. The CD14-expression was determined on whole blood monocytes by flow cytometry, while the LPS-binding of an FITC-LPS preparate and the LPS-induced TNFalpha secretion were tested on isolated monocytes. The CD14-dependent and -independent LPS-binding and activation were evaluated with the help of a blocking anti-CD14 mAb. Our results showed that the CD14-expression, CD14-dependent LPS-binding and activation were significantly inhibited by the in vivo applied pulse steroid therapy. In contrast, the CD14-independent LPS-binding and activation were not altered by the GCS treatment. Our data provide further in vivo evidence for a possible new way of GCS therapy is able to initiate its anti-inflammatory action.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Down-Regulation
  • Female
  • Glucocorticoids / therapeutic use*
  • Humans
  • Lipopolysaccharide Receptors / metabolism*
  • Lipopolysaccharides / immunology
  • Lipopolysaccharides / metabolism*
  • Lipopolysaccharides / pharmacology
  • Lupus Erythematosus, Systemic / drug therapy*
  • Lupus Erythematosus, Systemic / immunology
  • Male
  • Monocytes, Activated Killer / drug effects
  • Monocytes, Activated Killer / immunology*

Substances

  • Glucocorticoids
  • Lipopolysaccharide Receptors
  • Lipopolysaccharides